TheEdgeResearch
Home / Stocks / PMSNF

Proteome Sciences plc (PMSNF)

OTC Healthcare Medical - Specialties
$0.01 ▲ +0.00%
Market Cap
$2.9M
Sector
Healthcare
Industry
Medical - Specialties
Beta
0.15
52-Wk Range
0.01-0.04
CEO
Anil Wadhwani
Country
GB
Currency
USD

Proteome Sciences plc operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Cobham, SU, GB. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $2.9M. On trailing twelve-month figures it carries a trailing P/E of -1.33, a net margin of -61.5%. Its beta of 0.15 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.33
Price / Sales
0.90
Price / Book
-0.34
EV / EBITDA
-14.08
Gross margin
-25.4%
Operating margin
-60.6%
Net margin
-61.5%
Return on equity
—
Debt / equity
-1.61
Current ratio
0.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
32
IPO date
2010-02-22
Headquarters
Cobham, SU, GB
About Proteome Sciences plc

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Comparable companies

Proteome Sciences plc is most often compared with the following Healthcare names:

AIMLFANPCFAYURFBGXXCHMMFCNFHFGVDIIMTHNGMDFUNVC
More research on PMSNF
PMSNF technical analysis PMSNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →